GENELUX CORPORATION Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate
GENELUX CORPORATION (GNLX) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate of 109.00% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate · last filed 2026-08-13
- GENELUX CORPORATION share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2026-03-31 was 109.00%, a 9.00% increase year-over-year.
- GENELUX CORPORATION share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2025-03-31 was 100.00%.
- GENELUX CORPORATION share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2025 was 109.00%, a 9.00% increase from fiscal 2024.
- GENELUX CORPORATION share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2024 was 100.00%, a 0.00% change from fiscal 2023.
- GENELUX CORPORATION share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2023 was 100.00%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 12 month |
|---|---|---|---|---|
| 2026-06-30 | 109.00% 10-Q · filed 2026-08-13 | |||
| 2026-03-31 | 109.00% 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | 109.00% 10-K · filed 2026-03-19 | |||
| 2025-09-30 | 100.00% 10-Q · filed 2025-11-05 | |||
| 2025-06-30 | 100.00% 10-Q · filed 2026-08-13 | |||
| 2025-03-31 | 100.00% 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | 100.00% 10-K · filed 2026-03-19 | |||
| 2024-09-30 | 100.00% 10-Q · filed 2025-11-05 | |||
| 2024-06-30 | 100.00% 10-Q · filed 2025-08-07 | |||
| 2023-12-31 | 100.00% 10-K · filed 2025-03-28 | |||
| 2023-09-30 | 100.00% 10-Q · filed 2023-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |